https://news.medxy.ai/zh/dapirolizumab-sle-study/Medxy AIzh2026-09-22T05:41:33-07:00Dapirolizumab Pegol 改善系统性红斑狼疮疾病活动度：来自 PHOENYCS GO Ⅲ期试验及既往研究的证据 https://news.medxy.ai/ja/76203-2/Medxy AIja2026-09-22T05:41:05-07:00ダピロリズマブ・ペゴルによる全身性エリテマトーデスの疾患活動性の改善：PHOENYCS GO第III相試験および過去の研究からのエビデンス https://news.medxy.ai/vi/dapirolizumab-lupus/Medxy AIvi2026-09-22T05:40:27-07:00Dapirolizumab Pegol cải thiện hoạt tính bệnh ở lupus ban đỏ hệ thống: bằng chứng từ thử nghiệm pha 3 PHOENYCS GO và các nghiên cứu trước đó https://news.medxy.ai/dapirolizumab-pegol-improves-disease-activity-in-systemic-lupus-erythematosus-evidence-from-phase-3-phoenycs-go-trial-and-prior-studies/Medxy AIen2026-09-22T05:39:58-07:00Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior Studies https://news.medxy.ai/zh/gvhd-prevention-evolution/Medxy AIzh2026-09-22T05:36:55-07:00alloHSCT中GVHD预防的演变：来自西班牙大型真实世界队列的启示 https://news.medxy.ai/ja/gvhd-prevention-evolution-2/Medxy AIja2026-09-22T05:36:33-07:00同種造血幹細胞移植におけるGVHD予防の進化：スペイン大規模実臨床コホートからの示唆 https://news.medxy.ai/vi/gvhd-prophylaxis-allohsct/Medxy AIvi2026-09-22T05:36:09-07:00Dự phòng GVHD trong alloHSCT đang thay đổi: Góc nhìn từ một đoàn hệ thực tế quy mô lớn tại Tây Ban Nha https://news.medxy.ai/evolving-gvhd-prophylaxis-in-allohsct-insights-from-a-large-real-world-spanish-cohort/Medxy AIen2026-09-22T05:35:47-07:00Evolving GVHD Prophylaxis in AlloHSCT: Insights from a Large Real-World Spanish Cohort https://news.medxy.ai/zh/car-t-lymphoma-risks/Medxy AIzh2026-09-22T05:35:05-07:00揭示隐藏风险：CAR T细胞治疗后T细胞淋巴瘤——罕见但真实存在的隐忧 https://news.medxy.ai/ja/car-t-therapy-risks/Medxy AIja2026-09-22T05:34:43-07:00CAR T細胞療法後に潜む稀なリスク――T細胞リンパ腫を読み解く https://news.medxy.ai/vi/car-t-cell-therapy-risks/Medxy AIvi2026-09-22T05:34:18-07:00Hiểu rõ nguy cơ: U lympho tế bào T sau liệu pháp CAR T-cell therapy — mối lo hiếm gặp nhưng có thật https://news.medxy.ai/t-cell-lymphoma-risks/Medxy AIen2026-09-22T05:33:53-07:00Unraveling the Risks: T-Cell Lymphoma After CAR T-Cell Therapy—A Rare but Real Concern https://news.medxy.ai/zh/real-world-evidence-myeloma/Medxy AIzh2026-09-22T05:33:04-07:00全球真实世界证据：多发性骨髓瘤自体干细胞移植后维持治疗可带来生存获益 https://news.medxy.ai/ja/76183-2/Medxy AIja2026-09-22T05:32:42-07:00多発性骨髄腫における自家幹細胞移植後の維持療法は、生存上の利益をもたらす可能性がある https://news.medxy.ai/vi/stem-cell-transplant-survival/Medxy AIvi2026-09-22T05:32:20-07:00Bằng chứng thực tế toàn cầu cho thấy điều trị duy trì sau ghép tế bào gốc tự thân cải thiện sống còn ở đa u tủy https://news.medxy.ai/global-real-world-evidence-shows-survival-benefit-of-maintenance-therapy-post-autologous-stem-cell-transplant-in-multiple-myeloma/Medxy AIen2026-09-22T05:31:58-07:00Global Real-World Evidence Shows Survival Benefit of Maintenance Therapy Post-Autologous Stem Cell Transplant in Multiple Myeloma https://news.medxy.ai/zh/ai-fibrosis-diagnosis/Medxy AIzh2026-09-22T05:29:36-07:00AI赋能骨髓纤维化诊断：Continuous Indexing of Fibrosis（CIF）的临床评估 https://news.medxy.ai/ja/ai-fibrosis-diagnosis-2/Medxy AIja2026-09-22T05:29:15-07:00骨髄線維化診断を高精度化：AI駆動型Continuous Indexing of Fibrosis（CIF）の臨床評価 https://news.medxy.ai/vi/bone-marrow-fibrosis-diagnosis/Medxy AIvi2026-09-22T05:28:52-07:00Nâng cao chẩn đoán xơ hóa tủy xương: Đánh giá lâm sàng chỉ số liên tục xơ hóa do AI hỗ trợ (CIF) https://news.medxy.ai/enhancing-bone-marrow-fibrosis-diagnosis-clinical-evaluation-of-ai-driven-continuous-indexing-of-fibrosis-cif/Medxy AIen2026-09-22T05:28:26-07:00Enhancing Bone Marrow Fibrosis Diagnosis: Clinical Evaluation of AI-Driven Continuous Indexing of Fibrosis (CIF) https://news.medxy.ai/zh/76169-2/Medxy AIzh2026-09-22T05:27:46-07:00靶向IL-17A驱动的PTGS2/NLRP3炎性小体活性：针对PTPN11突变型JMML的新治疗策略 https://news.medxy.ai/ja/il-17a-ptgs2-nlrp3-targeting/Medxy AIja2026-09-22T05:27:21-07:00IL-17A駆動のPTGS2/NLRP3インフラマソーム活性を標的化：PTPN11変異JMMLに対する新たな治療戦略 https://news.medxy.ai/vi/il-17a-ptpn11-treatment/Medxy AIvi2026-09-22T05:26:53-07:00Nhắm trúng trục IL-17A thúc đẩy hoạt hóa PTGS2/NLRP3: hướng điều trị mới trong JMML đột biến PTPN11 https://news.medxy.ai/targeting-il-17a-driven-ptgs2-nlrp3-inflammasome-activation-a-novel-therapeutic-approach-in-ptpn11-mutant-juvenile-myelomonocytic-leukemia/Medxy AIen2026-09-22T05:26:27-07:00Targeting IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation: A Novel Therapeutic Approach in PTPN11-Mutant Juvenile Myelomonocytic Leukemia https://news.medxy.ai/zh/target-pkmyt1/Medxy AIzh2026-09-22T05:25:36-07:00靶向PKMYT1：高危del(17p)多发性骨髓瘤的潜在治疗新策略 https://news.medxy.ai/ja/pkmyt1-targeting/Medxy AIja2026-09-22T05:25:16-07:00PKMYT1を標的にする：del(17p)高リスク多発性骨髄腫に対する有望な治療戦略 https://news.medxy.ai/vi/target-pkmyt1-2/Medxy AIvi2026-09-22T05:24:52-07:00Nhắm vào PKMYT1: Chiến lược điều trị đầy hứa hẹn cho đa u tủy nguy cơ cao del(17p) https://news.medxy.ai/targeting-pkmyt1-a-promising-therapeutic-strategy-for-high-risk-del17p-multiple-myeloma/Medxy AIen2026-09-22T05:24:29-07:00Targeting PKMYT1: A Promising Therapeutic Strategy for High-Risk del(17p) Multiple Myeloma https://news.medxy.ai/zh/ibrutinib-venetoclax-lymphoma/Medxy AIzh2026-09-22T05:23:40-07:00老年及TP53突变非母细胞样套细胞淋巴瘤的一线伊布替尼联合维奈克拉：疗效与安全性 https://news.medxy.ai/ja/ibrutinib-benetoclax-treatment/Medxy AIja2026-09-22T05:23:18-07:00非芽球様マントル細胞リンパ腫に対するイブルチニブ＋ベネトクラクス一次治療：高齢者およびTP53変異例における有効性と安全性 https://news.medxy.ai/vi/ibrutinib-venetoclax-lymphoma-2/Medxy AIvi2026-09-22T05:22:53-07:00Ibrutinib phối hợp Venetoclax ở tuyến đầu cho u lympho tế bào áo thể không blastoid: Hiệu quả và độ an toàn ở người cao tuổi và bệnh nhân mang đột biến TP53 https://news.medxy.ai/first-line-ibrutinib-plus-venetoclax-in-nonblastoid-mantle-cell-lymphoma-efficacy-and-safety-in-older-adults-and-tp53-mutant-patients/Medxy AIen2026-09-22T05:22:28-07:00First-line Ibrutinib Plus Venetoclax in Nonblastoid Mantle Cell Lymphoma: Efficacy and Safety in Older Adults and TP53-Mutant Patients https://news.medxy.ai/zh/lung-transplant-kidney-impact/Medxy AIzh2026-09-22T05:21:40-07:002023年安全网政策对肺移植后肾移植的影响：移植实践与结局的早期变化 https://news.medxy.ai/ja/safety-net-impact-transplant/Medxy AIja2026-09-22T05:21:21-07:002023年safety net policyが肺移植後腎移植に与えた影響：移植診療と転帰の早期変化 https://news.medxy.ai/vi/safety-net-impact/Medxy AIvi2026-09-22T05:20:57-07:00Tác động của chính sách “safety net” năm 2023 đối với ghép thận sau ghép phổi: Những thay đổi sớm trong thực hành ghép và kết cục https://news.medxy.ai/impact-of-the-2023-safety-net-policy-on-kidney-after-lung-transplantation-early-changes-in-transplant-practices-and-outcomes/Medxy AIen2026-09-22T05:20:32-07:00Impact of the 2023 Safety Net Policy on Kidney After Lung Transplantation: Early Changes in Transplant Practices and Outcomes https://news.medxy.ai/zh/dupilumab-asthma-effects/Medxy AIzh2026-09-22T05:19:46-07:00CT视角下度普利尤单抗对中重度哮喘黏液栓动态及放射密度的影响 https://news.medxy.ai/ja/mucus-plug-dupilumab-effects/Medxy AIja2026-09-22T05:19:24-07:00中等症から重症喘息における粘液栓の変化と放射線濃度へのデュピルマブの影響：CT画像からみた解析 https://news.medxy.ai/vi/dupilumab-asthma-ct-2/Medxy AIvi2026-09-22T05:19:02-07:00Tác động của Dupilumab lên động học nút nhầy và mật độ tia X trong hen phế quản mức độ trung bình đến nặng: góc nhìn từ chẩn đoán hình ảnh CT https://news.medxy.ai/dupilumab-asthma-ct/Medxy AIen2026-09-22T05:18:37-07:00Dupilumab’s Impact on Mucus Plug Dynamics and Radiodensity in Moderate to Severe Asthma: A CT Imaging Perspective https://news.medxy.ai/zh/lung-cancer-screening-quality/Medxy AIzh2026-09-22T05:17:52-07:00远程医疗与面对面沟通下肺癌筛查共享决策质量：患者感知、证据综述与临床启示 https://news.medxy.ai/ja/76143-2/Medxy AIja2026-09-22T05:17:31-07:00遠隔医療と対面診療における肺がん検診の共有意思決定の質 https://news.medxy.ai/vi/patient-awareness-shared-decision-making/Medxy AIvi2026-09-22T05:17:02-07:00Nhận thức của bệnh nhân về chất lượng ra quyết định chung trong tầm soát ung thư phổi: so sánh giữa tư vấn từ xa và trao đổi trực tiếp, tổng hợp bằng chứng và góc nhìn lâm sàng https://news.medxy.ai/patient-perceptions-of-quality-of-shared-decision-making-for-lung-cancer-screening-in-telehealth-vs-in-person-discussions-a-synthesis-of-evidence-and-clinical-insights/Medxy AIen2026-09-22T05:16:37-07:00Patient Perceptions of Quality of Shared Decision-Making for Lung Cancer Screening in Telehealth vs In-Person Discussions: A Synthesis of Evidence and Clinical Insights https://news.medxy.ai/zh/bridging-eye-care-gap/Medxy AIzh2026-09-22T05:15:37-07:00弥合视力照护鸿沟：基于 CFIR 的美国社区成人眼筛查研究启示 https://news.medxy.ai/ja/ophthalmology-screening-challenges/Medxy AIja2026-09-22T05:15:14-07:00地域眼科スクリーニングの課題をどう越えるか：米国のCFIRガイド研究が示す示唆 https://news.medxy.ai/vi/eye-care-gap/Medxy AIvi2026-09-22T05:14:42-07:00Thu hẹp khoảng cách trong chăm sóc thị lực: Những phát hiện từ nghiên cứu định hướng CFIR về sàng lọc mắt cho người lớn dựa vào cộng đồng tại Hoa Kỳ https://news.medxy.ai/bridging-the-gap-in-vision-care-insights-from-a-cfir-guided-study-on-community-based-adult-eye-screening-in-the-u-s/Medxy AIen2026-09-22T05:14:16-07:00Bridging the Gap in Vision Care: Insights from a CFIR-Guided Study on Community-Based Adult Eye Screening in the U.S. https://news.medxy.ai/zh/76134-2/Medxy AIzh2026-09-22T05:13:30-07:00眼睑下垂综合征（Sagging Eye Syndrome）术后上斜视复发的研究 https://news.medxy.ai/ja/sagging-eye-syndrome/Medxy AIja2026-09-22T05:13:07-07:00Sagging Eye Syndromeにおける術後hypertropia再発の長期経過：知見と臨床的含意 https://news.medxy.ai/vi/76132-2/Medxy AIvi2026-09-22T05:12:41-07:00Diễn tiến dài hạn của tình trạng tái phát lác đứng lên (hypertropia) sau phẫu thuật ở bệnh nhân mắc hội chứng mắt xệ (Sagging Eye Syndrome) https://news.medxy.ai/long-term-recurrence-of-hypertropia-after-surgery-in-sagging-eye-syndrome-insights-and-implications/Medxy AIen2026-09-22T05:12:15-07:00Long-Term Recurrence of Hypertropia After Surgery in Sagging Eye Syndrome: Insights and Implications https://news.medxy.ai/zh/76129-2/Medxy AIzh2026-09-22T05:11:28-07:00超广角OCT揭示了伴有后巩膜葡萄肿的病理性近视中中央凹陷的形态及视神经乳头的特征 https://news.medxy.ai/ja/76128-2/Medxy AIja2026-09-22T05:11:04-07:00広範囲UWF-OCTが明らかにする、後部強膜ブリージアを伴う病的近視における黄斑部および視神経乳頭の形態的特徴 https://news.medxy.ai/vi/uwf-oct-central-nerve/Medxy AIvi2026-09-22T05:10:38-07:00UWF-OCT trường siêu rộng hé lộ địa hình hố trung tâm và đầu dây thần kinh thị giác khác biệt trong cận thị bệnh lý kèm phình lồi củng mạc sau https://news.medxy.ai/ultra-widefield-oct-reveals-distinct-foveal-and-optic-nerve-head-topography-in-pathologic-myopia-with-posterior-staphyloma/Medxy AIen2026-09-22T05:10:13-07:00Ultra-Widefield OCT Reveals Distinct Foveal and Optic Nerve Head Topography in Pathologic Myopia with Posterior Staphyloma https://news.medxy.ai/zh/pcv-treatment-outcomes/Medxy AIzh2026-09-22T05:09:27-07:00PCV完全消退后按需阿柏西普治疗的结局：临床综述 https://news.medxy.ai/ja/aflibercept-treatment-outcomes/Medxy AIja2026-09-22T05:09:02-07:00ポリープ状脈絡膜血管症における完全退縮後の必要時アフリベルセプト治療の転帰：臨床レビュー https://news.medxy.ai/vi/76122-2/Medxy AIvi2026-09-22T05:08:34-07:00Kết quả điều trị bằng aflibercept theo nhu cầu sau khi bệnh lý mạch hắc mạc đa giác (PCV) đã thoái lui hoàn toàn https://news.medxy.ai/outcomes-of-as-needed-aflibercept-treatment-after-complete-regression-in-polypoidal-choroidal-vasculopathy-a-clinical-review/Medxy AIen2026-09-22T05:08:02-07:00Outcomes of As-Needed Aflibercept Treatment After Complete Regression in Polypoidal Choroidal Vasculopathy: A Clinical Review https://news.medxy.ai/zh/76119-2/Medxy AIzh2026-09-22T05:07:08-07:00舒马曲坦（Susetiridine）能减少头颈部手术后阿片类药物使用 https://news.medxy.ai/ja/suzoterijin-opioid-use/Medxy AIja2026-09-22T05:06:48-07:00頭頸部手術後のオピオイド使用を抑えるスゼトリジンの役割：後ろ向きコホート解析 https://news.medxy.ai/vi/opioid-reduction-surgery/Medxy AIvi2026-09-22T05:06:25-07:00Suzetrigine giúp giảm sử dụng opioid sau phẫu thuật đầu cổ như thế nào? Phân tích đoàn hệ hồi cứu https://news.medxy.ai/suzetrigines-role-in-reducing-opioid-use-after-head-and-neck-surgery-a-retrospective-cohort-analysis/Medxy AIen2026-09-22T05:06:03-07:00Suzetrigine’s Role in Reducing Opioid Use After Head and Neck Surgery: A Retrospective Cohort Analysis https://news.medxy.ai/zh/rf-ablation-thyroid-nodules/Medxy AIzh2026-09-22T05:05:19-07:00射频消融：甲状腺叶切除术后甲状腺结节的微创替代方案 https://news.medxy.ai/ja/radiofrequency-ablation-options/Medxy AIja2026-09-22T05:05:00-07:00葉切除後の甲状腺結節に対する低侵襲選択肢：Radiofrequency Ablationの有用性 https://news.medxy.ai/vi/radiofrequency-ablation/Medxy AIvi2026-09-22T05:04:38-07:00Đốt sóng cao tần: Lựa chọn ít xâm lấn cho nhân giáp sau cắt thùy giáp https://news.medxy.ai/radiofrequency-ablation-a-minimally-invasive-alternative-for-thyroid-nodules-post-lobectomy/Medxy AIen2026-09-22T05:04:18-07:00Radiofrequency Ablation: A Minimally Invasive Alternative for Thyroid Nodules Post-Lobectomy https://news.medxy.ai/zh/cvemp-vhit-discrepancy/Medxy AIzh2026-09-22T05:03:37-07:00cVEMP与后半规管vHIT为何常不一致：1770只耳研究揭示前庭诊断新视角 https://news.medxy.ai/ja/vemp-vhit-comparison/Medxy AIja2026-09-22T05:03:13-07:00頸部VEMPと後半規管vHITは本当に同じ機能を見ているのか？―1770耳の解析から見えた前庭診断の新たな示唆 https://news.medxy.ai/vi/cvemp-vhit-difference/Medxy AIvi2026-09-22T05:02:48-07:00Sự phân ly chức năng giữa cVEMP cổ và vHIT ống bán khuyên sau: gợi ý mới cho chẩn đoán tiền đình trên 1770 tai không chọn lọc https://news.medxy.ai/functional-dissociation-of-cervical-vemp-and-posterior-canal-vhit-implications-for-vestibular-diagnostics-in-1770-unselected-ears/Medxy AIen2026-09-22T05:02:24-07:00Functional Dissociation of Cervical VEMP and Posterior Canal vHIT: Implications for Vestibular Diagnostics in 1770 Unselected Ears https://news.medxy.ai/zh/thyroid-compression-symptoms-2/Medxy AIzh2026-09-22T05:01:37-07:00甲状腺压迫性症状：优化诊断与治疗以改善预后 https://news.medxy.ai/ja/76103-2/Medxy AIja2026-09-22T05:01:16-07:00甲状腺による圧迫症状：予後改善に向けた診断と治療の最適化 https://news.medxy.ai/vi/thyroid-compression-symptoms/Medxy AIvi2026-09-22T05:00:51-07:00Triệu chứng chèn ép do tuyến giáp: Tối ưu hóa chẩn đoán và điều trị để cải thiện kết cục https://news.medxy.ai/thyroid-compressive-symptoms-optimizing-diagnosis-and-management-for-improved-outcomes/Medxy AIen2026-09-22T05:00:25-07:00Thyroid Compressive Symptoms: Optimizing Diagnosis and Management for Improved Outcomes https://news.medxy.ai/zh/laennec-robotic-liver-surgery/Medxy AIzh2026-09-21T06:59:37-07:00Laennec技术：推动右侧机器人供肝切除标准化的新路径 https://news.medxy.ai/ja/76098-2/Medxy AIja2026-09-21T06:59:19-07:00ラエンネック（Laennec）法：ロボット支援下右側ドナー肝切除の標準化を推進する新たなアプローチ https://news.medxy.ai/vi/laennec-robotic-right-hepatectomy/Medxy AIvi2026-09-21T06:58:58-07:00Kỹ thuật Laennec: Hướng tới chuẩn hóa cắt gan phải ở người hiến bằng robot https://news.medxy.ai/the-laennec-technique-advancing-standardization-in-right-robotic-donor-hepatectomies/Medxy AIen2026-09-21T06:58:35-07:00The Laennec Technique: Advancing Standardization in Right Robotic Donor Hepatectomies https://news.medxy.ai/zh/robotic-left-pancreatectomy/Medxy AIzh2026-09-21T06:57:58-07:00机器人辅助左侧胰腺切除术学习曲线评估：一项国际多中心研究中的安全性与肿瘤学结局 https://news.medxy.ai/ja/robotic-left-pancreatectomy-2/Medxy AIja2026-09-21T06:57:38-07:00ロボット支援左側膵切除術の学習曲線を検証する：国際多施設研究による安全性と腫瘍学的転帰 https://news.medxy.ai/vi/robotic-left-pancreatectomy-learning-curve/Medxy AIvi2026-09-21T06:57:09-07:00Đánh giá đường cong học tập của cắt tụy trái hỗ trợ bằng robot: an toàn và kết cục ung bướu trong một nghiên cứu đa trung tâm quốc tế https://news.medxy.ai/assessing-the-learning-curve-of-robotic-left-sided-pancreatectomy-safety-and-oncological-outcomes-in-a-multicenter-international-study/Medxy AIen2026-09-21T06:56:47-07:00Assessing the Learning Curve of Robotic Left-Sided Pancreatectomy: Safety and Oncological Outcomes in a Multicenter International Study https://news.medxy.ai/zh/reduce-coronary-perfusion-risk/Medxy AIzh2026-09-21T06:56:03-07:00降低生物瓣主动脉根部置换中冠状动脉灌注不良风险的策略 https://news.medxy.ai/ja/coronary-flow-strategy/Medxy AIja2026-09-21T06:55:38-07:00生体人工弁大動脈基部置換における冠灌流障害を抑える戦略 https://news.medxy.ai/vi/reducing-coronary-ischemia/Medxy AIvi2026-09-21T06:55:12-07:00Chiến lược giảm thiểu thiếu máu tưới máu vành trong thay gốc động mạch chủ bằng van sinh học https://news.medxy.ai/strategies-to-minimize-coronary-malperfusion-in-bioprosthetic-aortic-root-replacement/Medxy AIen2026-09-21T06:54:48-07:00Strategies to Minimize Coronary Malperfusion in Bioprosthetic Aortic Root Replacement https://news.medxy.ai/zh/trauma-communication-gap/Medxy AIzh2026-09-21T06:54:04-07:00创伤救治中的沟通鸿沟：评估创伤复苏室内的创伤知情沟通 https://news.medxy.ai/ja/trauma-informed-communication/Medxy AIja2026-09-21T06:53:46-07:00外傷ベイにおけるトラウマ配慮型コミュニケーションを検証する：外傷ケアのギャップを埋める視点 https://news.medxy.ai/vi/trauma-care-communication/Medxy AIvi2026-09-21T06:53:20-07:00Thu hẹp khoảng cách trong chăm sóc chấn thương: Đánh giá giao tiếp theo hướng lưu ý đến sang chấn tại khu cấp cứu chấn thương https://news.medxy.ai/bridging-gaps-in-trauma-care-assessing-trauma-informed-communication-in-the-trauma-bay/Medxy AIen2026-09-21T06:52:55-07:00Bridging Gaps in Trauma Care: Assessing Trauma-Informed Communication in the Trauma Bay https://news.medxy.ai/zh/robotic-vs-laparoscopic-cholecystectomy-2/Medxy AIzh2026-09-21T06:52:11-07:00机器人胆囊切除术还是腹腔镜胆囊切除术？安全性、疗效与成本的权衡及新型风险计算器 https://news.medxy.ai/ja/robotic-vs-laparoscopic/Medxy AIja2026-09-21T06:51:51-07:00ロボット支援か腹腔鏡下か：新規リスク算出ツールでみる胆嚢摘出術の安全性・有効性・費用の最適な釣り合い https://news.medxy.ai/vi/robotic-gallbladder-surgery-2/Medxy AIvi2026-09-21T06:51:24-07:00Cắt túi mật bằng robot hay nội soi: Cân bằng an toàn, hiệu quả và chi phí với một công cụ dự đoán nguy cơ mới https://news.medxy.ai/robotic-versus-laparoscopic-cholecystectomy-balancing-safety-efficacy-and-cost-with-a-novel-risk-calculator/Medxy AIen2026-09-21T06:51:03-07:00Robotic Versus Laparoscopic Cholecystectomy: Balancing Safety, Efficacy, and Cost with a Novel Risk Calculator https://news.medxy.ai/zh/opioid-prescription-optimization/Medxy AIzh2026-09-21T06:50:21-07:00腹腔癌症术后阿片类药物出院处方如何优化：5倍乘数模型与三层模型的比较 https://news.medxy.ai/ja/optimize-opioid-prescription/Medxy AIja2026-09-21T06:50:03-07:00腹腔内がん手術後の退院時オピオイド処方を最適化する：5倍乗数モデルと3段階モデルの比較 https://news.medxy.ai/vi/opioid-prescription-optimization-2/Medxy AIvi2026-09-21T06:49:41-07:00Tối ưu hóa kê đơn opioid sau phẫu thuật ung thư trong ổ bụng: So sánh mô hình nhân 5 và mô hình 3 bậc https://news.medxy.ai/optimizing-postoperative-opioid-prescriptions-after-intra-abdominal-cancer-surgery-comparing-the-5x-multiplier-and-3-tier-models/Medxy AIen2026-09-21T06:49:23-07:00Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models https://news.medxy.ai/zh/rhd-antibody-formation/Medxy AIzh2026-09-21T06:48:45-07:00Rh(D) 阳性全血与 Rh(D) 阴性红细胞：创伤复苏后早期同种抗体形成的发生率及其意义 https://news.medxy.ai/ja/rh-positive-vs-rh-negative-blood/Medxy AIja2026-09-21T06:48:19-07:00外傷蘇生におけるRh(D)陽性全血とRh(D)陰性赤血球製剤：早期同種抗体形成の発生率と臨床的意義 https://news.medxy.ai/vi/antibody-formation-rates/Medxy AIvi2026-09-21T06:47:55-07:00Tỷ lệ và ý nghĩa của sự hình thành kháng thể bất đồng nhóm sớm sau hồi sức chấn thương bằng máu toàn phần Rh(D)+ so với hồng cầu Rh(D)- https://news.medxy.ai/incidence-and-implications-of-early-alloantibody-formation-after-trauma-resuscitation-with-rhd-whole-blood-versus-rhd-red-blood-cells/Medxy AIen2026-09-21T06:47:32-07:00Incidence and Implications of Early Alloantibody Formation After Trauma Resuscitation With Rh(D)+ Whole Blood Versus Rh(D)- Red Blood Cells https://news.medxy.ai/zh/gist-exon11-surgery/Medxy AIzh2026-09-21T06:46:47-07:00KIT 外显子 11 突变型 GIST 何时手术更合适？新辅助伊马替尼后影像学与病理学反应的启示 https://news.medxy.ai/ja/optimal-surgery-timing-gist/Medxy AIja2026-09-21T06:46:24-07:00KIT exon 11変異GISTにおける最適手術時期：ネオアジュバントimatinib後の画像評価と病理統合評価からみた示唆 https://news.medxy.ai/vi/optimal-gist-surgery/Medxy AIvi2026-09-21T06:45:55-07:00Thời điểm phẫu thuật tối ưu trong GIST đột biến KIT exon 11: Góc nhìn từ đáp ứng tích hợp hình ảnh và giải phẫu bệnh sau imatinib tân bổ trợ https://news.medxy.ai/optimal-surgical-timing-in-kit-exon-11-mutant-gist-insights-from-radiographic-and-pathology-integrated-responses-after-neoadjuvant-imatinib/Medxy AIen2026-09-21T06:45:31-07:00Optimal Surgical Timing in KIT Exon 11-Mutant GIST: Insights from Radiographic and Pathology-Integrated Responses After Neoadjuvant Imatinib https://news.medxy.ai/zh/avutometinib-defactinib-safety/Medxy AIzh2026-09-21T06:44:49-07:00复发性低级别浆液性卵巢癌中 Avutometinib 联合 Defactinib 的持久疗效与安全性：基于 ENGOT-OV60/GOG-3052/RAMP 201 2 年随访的解析 https://news.medxy.ai/ja/avutometinib-defactinib-ovarian-cancer/Medxy AIja2026-09-21T06:44:26-07:00再発低悪性度漿液性卵巣癌に対するAvutometinib＋Defactinibの持続的有効性と安全性：ENGOT-OV60/GOG-3052/RAMP 201の2年追跡解析 https://news.medxy.ai/vi/76057-2/Medxy AIvi2026-09-21T06:44:01-07:00Hiệu quả lâu dài và độ an toàn của Avutometinib kết hợp với Defactinib trong điều trị ung thư buồng trứng thể tuyến thanh dịch độ thấp tái phát: Phân tích dựa trên theo dõi 2 năm từ nghiên cứu ENGOT-OV60/GOG-3052/RAMP 201 https://news.medxy.ai/durable-efficacy-and-safety-of-avutometinib-plus-defactinib-in-recurrent-low-grade-serous-ovarian-cancer-insights-from-a-2-year-engot-ov60-gog-3052-ramp-201-follow-up/Medxy AIen2026-09-21T06:43:33-07:00Durable Efficacy and Safety of Avutometinib plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from a 2-Year ENGOT-OV60/GOG-3052/RAMP 201 Follow-up https://news.medxy.ai/zh/liver-cirrhosis-fall-prevention/Medxy AIzh2026-09-21T06:42:42-07:00乳果糖序贯联用 TeleTai-Chi：肝硬化患者跌倒预防的新策略 https://news.medxy.ai/ja/fall-prevention-cirrhosis/Medxy AIja2026-09-21T06:42:21-07:00肝硬変の転倒予防に挑む：ラクツロースと TeleTai-Chi を段階的に用いた LiveSMART 試験の知見 https://news.medxy.ai/vi/76052-2/Medxy AIvi2026-09-21T06:41:58-07:00Sử dụng tuần tự Lactulose và Tele-Tai Chi: Một chiến lược mới nhằm phòng ngừa té ngã ở bệnh nhân xơ gan https://news.medxy.ai/sequential-lactulose-and-teletai-chi-to-prevent-falls-in-cirrhosis-insights-from-the-livesmart-trial/Medxy AIen2026-09-21T06:41:31-07:00Sequential Lactulose and TeleTai-Chi to Prevent Falls in Cirrhosis: Insights from the LiveSMART Trial https://news.medxy.ai/zh/gut-microbiome-liver-cancer-2/Medxy AIzh2026-09-21T06:40:43-07:00肠道微生物组动态变化有望提升晚期肝癌免疫治疗获益预测 https://news.medxy.ai/ja/gut-microbiome-liver-cancer/Medxy AIja2026-09-21T06:40:22-07:00進行性肝癌の免疫療法成績を高める腸内マイクロバイオームの動的変化 https://news.medxy.ai/vi/gut-microbiome-therapy/Medxy AIvi2026-09-21T06:39:56-07:00Biến đổi động của hệ vi sinh đường ruột giúp nâng cao kết quả miễn dịch trị liệu ở ung thư gan giai đoạn tiến xa https://news.medxy.ai/dynamic-gut-microbiome-changes-enhance-immunotherapy-outcomes-in-advanced-liver-cancer/Medxy AIen2026-09-21T06:39:29-07:00Dynamic Gut Microbiome Changes Enhance Immunotherapy Outcomes in Advanced Liver Cancer https://news.medxy.ai/zh/hbv-immunosuppressive-macrophages/Medxy AIzh2026-09-21T06:38:48-07:00HBV诱导的免疫抑制性巨噬细胞：驱动慢性乙型肝炎持续存在的代谢与表观遗传通路 https://news.medxy.ai/ja/hbv-induced-macrophages/Medxy AIja2026-09-21T06:38:24-07:00HBVが誘導する免疫抑制性マクロファージ：慢性B型肝炎の持続を支える代謝・エピジェネティック経路 https://news.medxy.ai/vi/76042-2/Medxy AIvi2026-09-21T06:37:58-07:00Đại thực bào ức chế miễn dịch do HBV: Các con đường chuyển hóa và biểu di truyền thúc đẩy sự tồn tại dai dẳng của viêm gan B mạn tính https://news.medxy.ai/hbv-induced-immunosuppressive-macrophages-metabolic-and-epigenetic-pathways-driving-chronic-hepatitis-b-persistence/Medxy AIen2026-09-21T06:37:29-07:00HBV-Induced Immunosuppressive Macrophages: Metabolic and Epigenetic Pathways Driving Chronic Hepatitis B Persistence https://news.medxy.ai/zh/pancreatitis-pain-treatment/Medxy AIzh2026-09-21T06:36:44-07:00非肠溶包衣胰酶治疗慢性胰腺炎疼痛：一项高质量随机试验带来的启示 https://news.medxy.ai/ja/pancreatitis-pain-relief/Medxy AIja2026-09-21T06:36:20-07:00慢性膵炎の疼痛緩和に対する非腸溶性膵酵素療法を検証する：堅牢な無作為化試験からの知見 https://news.medxy.ai/vi/pancreatic-enzyme-therapy-pain/Medxy AIvi2026-09-21T06:35:53-07:00Đánh giá liệu pháp enzym tụy không bao tan ruột trong giảm đau do viêm tụy mạn: dữ liệu từ một thử nghiệm ngẫu nhiên quy mô lớn https://news.medxy.ai/evaluating-non-enteric-coated-pancreatic-enzyme-therapy-for-pain-relief-in-chronic-pancreatitis-insights-from-a-robust-randomized-trial/Medxy AIen2026-09-21T06:35:30-07:00Evaluating Non-Enteric-Coated Pancreatic Enzyme Therapy for Pain Relief in Chronic Pancreatitis: Insights from a Robust Randomized Trial https://news.medxy.ai/zh/microbiome-therapy-advances/Medxy AIzh2026-09-21T06:34:46-07:00精准微生物组治疗新进展：Faecalibacterium prausnitzii EXL01 预防多次复发性艰难拟梭菌感染 https://news.medxy.ai/ja/microbiome-treatment-clostridioides-prevention/Medxy AIja2026-09-21T06:34:21-07:00精密マイクロバイオーム治療の新展開：多発再発性 Clostridioides difficile 感染症予防における Faecalibacterium prausnitzii EXL01 https://news.medxy.ai/vi/76032-2/Medxy AIvi2026-09-21T06:33:53-07:00Faecalibacterium prausnitzii EXL01 để phòng ngừa tái phát nhiễm khuẩn Clostridioides difficile https://news.medxy.ai/precision-microbiome-therapeutics-faecalibacterium-prausnitzii-exl01-for-prevention-of-multiple-recurrent-clostridioides-difficile-infection/Medxy AIen2026-09-21T06:33:27-07:00Precision Microbiome Therapeutics: Faecalibacterium prausnitzii EXL01 for Prevention of Multiple-Recurrent Clostridioides difficile Infection https://news.medxy.ai/zh/cdkl5-eeg-seizures/Medxy AIzh2026-09-21T06:32:23-07:00早期 CDKL5 缺陷障碍中的 EEG 演变与发作特征：对发育结局的启示 https://news.medxy.ai/ja/cdkl5-eeg-seizures-2/Medxy AIja2026-09-21T06:31:59-07:00CDKL5欠損症乳幼児におけるEEGの推移と発作特徴：発達予後への示唆 https://news.medxy.ai/vi/cdkl5-seizure-progress/Medxy AIvi2026-09-21T06:31:34-07:00Diễn tiến EEG và đặc điểm cơn co giật trong giai đoạn sớm của rối loạn thiếu hụt CDKL5: hàm ý đối với kết cục phát triển https://news.medxy.ai/eeg-evolution-and-seizure-characteristics-in-early-cdkl5-deficiency-disorder-implications-for-developmental-outcomes/Medxy AIen2026-09-21T06:31:11-07:00EEG Evolution and Seizure Characteristics in Early CDKL5 Deficiency Disorder: Implications for Developmental Outcomes https://news.medxy.ai/zh/veterans-explosion-health/Medxy AIzh2026-09-21T06:30:27-07:00退伍军人军事爆炸暴露的长期健康影响：来自 Millennium Cohort Study 的启示 https://news.medxy.ai/ja/military-blast-exposure-risks/Medxy AIja2026-09-21T06:30:04-07:00軍務中の爆風曝露は退役後の健康にどう影響するか：ミレニアム・コホート研究が示す長期的リスク https://news.medxy.ai/vi/long-term-health-effects/Medxy AIvi2026-09-21T06:29:37-07:00Ảnh hưởng sức khỏe lâu dài của phơi nhiễm nổ trong quân đội ở cựu chiến binh: Những phát hiện từ Millennium Cohort Study https://news.medxy.ai/long-term-health-impacts-of-military-blast-exposure-on-veterans-insights-from-the-millennium-cohort-study/Medxy AIen2026-09-21T06:29:12-07:00Long-Term Health Impacts of Military Blast Exposure on Veterans: Insights from the Millennium Cohort Study https://news.medxy.ai/zh/pituitary-adenoma-subtypes/Medxy AIzh2026-09-21T06:28:30-07:00垂体腺瘤的组织学亚型：对肢端肥大症手术结局与疾病控制的影响 https://news.medxy.ai/ja/pituitary-adenoma-subtypes-2/Medxy AIja2026-09-21T06:28:04-07:00下垂体腺腫の組織学的サブタイプ：先端巨大症における手術成績と疾患コントロールへの影響 https://news.medxy.ai/vi/pituitary-adenoma-classification/Medxy AIvi2026-09-21T06:27:38-07:00Phân nhóm mô học của u tuyến yên: Vai trò trong kết cục phẫu thuật và kiểm soát bệnh ở bệnh to đầu chi https://news.medxy.ai/histological-subtypes-of-pituitary-adenomas-their-role-in-acromegaly-surgical-outcomes-and-disease-control/Medxy AIen2026-09-21T06:27:09-07:00Histological Subtypes of Pituitary Adenomas: Their Role in Acromegaly Surgical Outcomes and Disease Control https://news.medxy.ai/zh/anaplastic-thyroid-cancer-chemotherapy/Medxy AIzh2026-09-21T06:26:22-07:00德国多中心注册研究：间变性甲状腺癌一线化疗策略的疗效评估 https://news.medxy.ai/ja/undifferentiated-thyroid-cancer-chemotherapy/Medxy AIja2026-09-21T06:25:59-07:00未分化甲状腺がんの一次化学療法を再考する：ドイツ多施設レジストリからの知見 https://news.medxy.ai/vi/thyroid-cancer-treatment-2/Medxy AIvi2026-09-21T06:25:37-07:00Đánh giá chiến lược hóa trị tuyến đầu trong ung thư tuyến giáp không biệt hóa: Góc nhìn từ một đăng ký đa trung tâm tại Đức https://news.medxy.ai/evaluating-first-line-chemotherapy-strategies-in-anaplastic-thyroid-cancer-insights-from-a-german-multicenter-registry/Medxy AIen2026-09-21T06:25:15-07:00Evaluating First-Line Chemotherapy Strategies in Anaplastic Thyroid Cancer: Insights from a German Multicenter Registry https://news.medxy.ai/zh/cushing-disease-remission/Medxy AIzh2026-09-21T06:24:27-07:00库欣病长期缓解后血浆蛋白异常仍持续存在：对发病风险与监测的启示 https://news.medxy.ai/ja/cushing-disease-biomarkers/Medxy AIja2026-09-21T06:24:02-07:00クッシング病の長期寛解後も残る血漿タンパク質異常――罹患リスクと経過観察への示唆 https://news.medxy.ai/vi/cushing-syndrome-longterm/Medxy AIvi2026-09-21T06:23:32-07:00Bệnh Cushing sau thuyên giảm lâu dài: các bất thường protein huyết tương dai dẳng và ý nghĩa đối với bệnh tật, theo dõi https://news.medxy.ai/persistent-plasma-protein-alterations-after-long-term-remission-in-cushings-disease-implications-for-morbidity-and-monitoring/Medxy AIen2026-09-21T06:23:07-07:00Persistent Plasma Protein Alterations After Long-Term Remission in Cushing’s Disease: Implications for Morbidity and Monitoring https://news.medxy.ai/zh/type-1-diabetes-trajectories/Medxy AIzh2026-09-21T06:22:20-07:001型糖尿病成人的长期血糖轨迹：一项3年多中心CGM研究的启示 https://news.medxy.ai/ja/type-1-diabetes-trends/Medxy AIja2026-09-21T06:21:56-07:001型糖尿病成人における血糖推移の縦断解析：3年間の多施設CGM研究からの示唆 https://news.medxy.ai/vi/vertical-glucose-trajectory/Medxy AIvi2026-09-21T06:21:29-07:00Quỹ đạo đường huyết theo chiều dọc ở người lớn mắc đái tháo đường típ 1: Góc nhìn từ nghiên cứu đa trung tâm CGM kéo dài 3 năm https://news.medxy.ai/longitudinal-glycemic-trajectories-in-adults-with-type-1-diabetes-insights-from-a-three-year-multicenter-cgm-study/Medxy AIen2026-09-21T06:21:04-07:00Longitudinal Glycemic Trajectories in Adults with Type 1 Diabetes: Insights from a Three-Year Multicenter CGM Study https://news.medxy.ai/zh/pregnancy-pcos-outcomes/Medxy AIzh2026-09-21T06:20:15-07:00妊娠期多内分泌代谢性卵巢综合征与母婴结局：一项嵌套前瞻性队列研究的启示 https://news.medxy.ai/ja/pcos-pregnancy-effects/Medxy AIja2026-09-21T06:19:52-07:00妊娠中のポリ内分泌代謝性卵巣症候群が母体・新生児転帰に及ぼす影響：ネスト型前向きコホート研究からの知見 https://news.medxy.ai/vi/75973-2/Medxy AIvi2026-09-21T06:19:22-07:00Hội chứng buồng trứng đa nang trong thai kỳ và kết cục đối với mẹ và con https://news.medxy.ai/maternal-and-neonatal-outcomes-associated-with-polyendocrine-metabolic-ovarian-syndrome-during-pregnancy-insights-from-a-nested-prospective-cohort-study/Medxy AIen2026-09-21T06:18:57-07:00Maternal and Neonatal Outcomes Associated with Polyendocrine Metabolic Ovarian Syndrome During Pregnancy: Insights from a Nested Prospective Cohort Study https://news.medxy.ai/zh/diabetes-management-alerts/Medxy AIzh2026-09-21T06:18:10-07:00从预警到行动：借助电子健康记录提醒提升糖尿病自我管理转诊 https://news.medxy.ai/ja/alert-action-diabetes/Medxy AIja2026-09-21T06:17:50-07:00アラートを行動へ：電子カルテのアラートで糖尿病自己管理支援紹介を強化する https://news.medxy.ai/vi/diabetes-care-alerts/Medxy AIvi2026-09-21T06:17:30-07:00Từ cảnh báo đến hành động: Nâng cao chuyển tuyến giáo dục tự quản lý đái tháo đường qua cảnh báo trên hồ sơ sức khỏe điện tử https://news.medxy.ai/from-alert-to-action-enhancing-diabetes-self-management-referrals-through-electronic-health-record-alerts/Medxy AIen2026-09-21T06:17:08-07:00From Alert to Action: Enhancing Diabetes Self-Management Referrals Through Electronic Health Record Alerts https://news.medxy.ai/zh/semaglutide-efficacy-safety/Medxy AIzh2026-09-21T06:16:28-07:00司美格鲁肽在不同虚弱状态下的疗效与安全性：基于SELECT随机临床试验事后分析的启示 https://news.medxy.ai/ja/semaglutide-efficacy-safety-2/Medxy AIja2026-09-21T06:16:02-07:00フレイル状態別にみたセマグルチドの有効性と安全性：SELECTランダム化臨床試験の事後解析からの示唆 https://news.medxy.ai/vi/semaglutide-frailty/Medxy AIvi2026-09-21T06:15:33-07:00Semaglutide: Hiệu quả và độ an toàn theo tình trạng frailty từ phân tích hậu kiểm thử nghiệm lâm sàng ngẫu nhiên SELECT https://news.medxy.ai/efficacy-and-safety-of-semaglutide-according-to-frailty-status-insights-from-the-select-randomized-clinical-trial-post-hoc-analysis/Medxy AIen2026-09-21T06:15:04-07:00Efficacy and Safety of Semaglutide According to Frailty Status: Insights from the SELECT Randomized Clinical Trial Post Hoc Analysis https://news.medxy.ai/ja/whole-grains-metabolic-risk/Medxy AIja2026-09-21T05:46:13-07:00全粒穀物の摂取は心代謝リスクを下げるか：ランダム化試験のメタ解析 https://news.medxy.ai/vi/whole-grains-heart-risk/Medxy AIvi2026-09-21T05:45:50-07:00Ngũ cốc nguyên hạt và nguy cơ tim mạch – chuyển hóa: Phân tích tổng hợp từ các thử nghiệm ngẫu nhiên https://news.medxy.ai/whole-grain-consumption-and-cardiometabolic-risk-a-meta-analysis-of-randomized-trials/Medxy AIen2026-09-21T05:45:25-07:00Whole-grain Consumption and Cardiometabolic Risk: A Meta-analysis of Randomized Trials https://news.medxy.ai/zh/75928-2/Medxy AIzh2026-09-21T05:44:35-07:00心脏压力负荷时代谢应激可能加剧蒽环类药物的心脏毒性 https://news.medxy.ai/ja/anthracycline-cardiotoxicity/Medxy AIja2026-09-21T05:44:02-07:00圧負荷心における代謝ストレスが増幅するアントラサイクリン心毒性：機序的理解と臨床的意義 https://news.medxy.ai/vi/anthracycline-heart-toxicity/Medxy AIvi2026-09-21T05:43:35-07:00Độc tính tim do anthracycline bị thúc đẩy bởi stress chuyển hóa ở tim quá tải áp lực: cơ chế và ý nghĩa lâm sàng https://news.medxy.ai/anthracycline-cardiotoxicity-exacerbated-by-metabolic-stress-in-pressure-overloaded-hearts-mechanistic-insights-and-clinical-implications/Medxy AIen2026-09-21T05:43:03-07:00Anthracycline Cardiotoxicity Exacerbated by Metabolic Stress in Pressure-Overloaded Hearts: Mechanistic Insights and Clinical Implications https://news.medxy.ai/zh/hpv16-head-neck-cancer/Medxy AIzh2026-09-21T05:42:19-07:00HPV16 阳性复发/转移性头颈癌迎来新希望：VERSATILE-002Ⅱ期研究揭示免疫联合治疗潜力 https://news.medxy.ai/ja/hpv16-recurrence-treatment/Medxy AIja2026-09-21T05:41:57-07:00HPV16陽性再発・転移性頭頸部癌で新規免疫療法併用に期待：VERSATILE-002第2相試験から見えた可能性 https://news.medxy.ai/vi/immune-combination-hpv16/Medxy AIvi2026-09-21T05:41:28-07:00Phối hợp miễn dịch mới cho kết quả khả quan ở ung thư đầu cổ tái phát/di căn dương tính HPV16: Góc nhìn từ thử nghiệm pha 2 VERSATILE-002 https://news.medxy.ai/novel-immunotherapy-combination-shows-promise-in-hpv16-positive-r-m-head-and-neck-cancer-insights-from-the-versatile-002-phase-2-trial/Medxy AIen2026-09-21T05:41:02-07:00Novel Immunotherapy Combination Shows Promise in HPV16-Positive R/M Head and Neck Cancer: Insights from the VERSATILE-002 Phase 2 Trial https://news.medxy.ai/zh/low-pdl1-head-neck-cancer/Medxy AIzh2026-09-21T05:40:15-07:00低 PD-L1 表达头颈鳞状细胞癌的免疫治疗：一项关于生存结局的荟萃分析洞见 https://news.medxy.ai/ja/pd-l1-low-headneck-cancer/Medxy AIja2026-09-21T05:39:46-07:00PD-L1低発現頭頸部扁平上皮癌における免疫療法：生存転帰を読み解くメタ解析の知見 https://news.medxy.ai/vi/75916-2/Medxy AIvi2026-09-21T05:39:12-07:00Liệu pháp miễn dịch trong ung thư biểu mô tế bào vảy vùng đầu cổ có biểu hiện PD-L1 thấp https://news.medxy.ai/immunotherapy-in-head-and-neck-squamous-cell-carcinoma-with-low-pd-l1-expression-a-meta-analytic-insight-into-survival-outcomes/Medxy AIen2026-09-21T05:38:48-07:00Immunotherapy in Head and Neck Squamous Cell Carcinoma with Low PD-L1 Expression: A Meta-Analytic Insight into Survival Outcomes https://news.medxy.ai/zh/at2-tgf-beta1-platelet-thrombosis/Medxy AIzh2026-09-21T05:14:03-07:00揭示血管紧张素Ⅱ驱动的TGF-β1在高血压中增强血小板PAR4表达及血栓风险中的作用 https://news.medxy.ai/ja/angiotensin-tgf-beta-thrombosis/Medxy AIja2026-09-21T05:13:42-07:00アンジオテンシンII―TGF-β1軸が血小板PAR4を高める機序と高血圧における血栓リスクの新知見 https://news.medxy.ai/vi/tgf-beta1-par4-thrombosis/Medxy AIvi2026-09-21T05:13:19-07:00Khám phá vai trò của TGF-β1 do Angiotensin II dẫn dắt trong việc làm tăng biểu hiện PAR4 trên tiểu cầu và nguy cơ huyết khối ở tăng huyết áp https://news.medxy.ai/angiotensin-tgf-beta-thrombosis-2/Medxy AIen2026-09-21T05:12:54-07:00Unveiling the Role of Angiotensin II-Driven TGF-β1 in Enhancing Platelet PAR4 Expression and Thrombotic Risk in Hypertension https://news.medxy.ai/zh/low-dose-rivaroxaban/Medxy AIzh2026-09-20T09:24:56-07:00重度慢性肾脏病合并高心血管风险患者低剂量利伐沙班的疗效与安全性：综合综述 https://news.medxy.ai/ja/low-dose-rivaroxaban-ckd/Medxy AIja2026-09-20T09:24:31-07:00高心血管リスクを伴う進行期慢性腎臓病における低用量リバーロキサバンの有効性と安全性：包括的レビュー https://news.medxy.ai/vi/75900-2/Medxy AIvi2026-09-20T09:24:05-07:00Hiệu quả và độ an toàn của rivaroxaban liều thấp ở bệnh nhân mắc bệnh thận mạn giai đoạn tiến triển và có nguy cơ tim mạch cao https://news.medxy.ai/efficacy-and-safety-of-low-dose-rivaroxaban-in-advanced-chronic-kidney-disease-with-high-cardiovascular-risk-a-comprehensive-review/Medxy AIen2026-09-20T09:23:39-07:00Efficacy and Safety of Low-Dose Rivaroxaban in Advanced Chronic Kidney Disease with High Cardiovascular Risk: A Comprehensive Review https://news.medxy.ai/zh/pd-l1-pd-l2-b-cell-lymphoma-2/Medxy AIzh2026-09-20T09:22:45-07:00PD-L1与PD-L2在原发性纵隔大B细胞淋巴瘤中的不同作用：对免疫治疗的启示 https://news.medxy.ai/ja/pd-l1-pd-l2-roles/Medxy AIja2026-09-20T09:22:22-07:00原発性縦隔大細胞型B細胞リンパ腫におけるPD-L1とPD-L2の異なる役割：免疫治療への示唆 https://news.medxy.ai/vi/pd-l1-pd-l2-b-cell-lymphoma/Medxy AIvi2026-09-20T09:21:57-07:00Vai trò khác biệt của PD-L1 và PD-L2 trong u lympho tế bào B lớn nguyên phát trung thất: hàm ý cho miễn dịch trị liệu https://news.medxy.ai/distinct-roles-of-pd-l1-and-pd-l2-in-primary-mediastinal-large-b-cell-lymphoma-implications-for-immune-therapeutics/Medxy AIen2026-09-20T09:21:34-07:00Distinct Roles of PD-L1 and PD-L2 in Primary Mediastinal Large B-Cell Lymphoma: Implications for Immune Therapeutics https://news.medxy.ai/zh/neutrophil-driven-hemophilic-arthritis/Medxy AIzh2026-09-20T09:20:46-07:00中性粒细胞驱动的血友病性关节病干扰素病变：潜在新靶点的揭示 https://news.medxy.ai/ja/hemophilic-arthritis-research/Medxy AIja2026-09-20T09:20:25-07:00血友病性関節症における好中球駆動型インターフェロン病の解明：新たな治療標的 https://news.medxy.ai/vi/interferonopathy-treatment/Medxy AIvi2026-09-20T09:19:55-07:00Giải mã interferonopathy do bạch cầu trung tính trong bệnh khớp do máu khó đông: một đích điều trị mới https://news.medxy.ai/unraveling-neutrophil-driven-interferonopathy-in-hemophilic-arthropathy-a-new-therapeutic-target/Medxy AIen2026-09-20T09:19:28-07:00Unraveling Neutrophil-Driven Interferonopathy in Hemophilic Arthropathy: A New Therapeutic Target https://news.medxy.ai/zh/mycobacterium-massiliense/Medxy AIzh2026-09-20T09:18:45-07:00东亚特异性 Mycobacterium massiliense ST120：系统发育基因组学、临床影响与肺部疾病管理挑战 https://news.medxy.ai/ja/mycobacterium-massiliense-east-asia/Medxy AIja2026-09-20T09:18:23-07:00東アジアに特有な Mycobacterium massiliense ST120：系統ゲノム解析、臨床的影響、そして肺疾患管理の課題 https://news.medxy.ai/vi/75872-2/Medxy AIvi2026-09-20T09:17:59-07:00Những thách thức trong việc quản lý bệnh phổi do chủng *Mycobacterium massiliense* ST120 đặc thù tại Đông Á gây ra https://news.medxy.ai/east-asia-specific-mycobacterium-massiliense-st120-phylogenomics-clinical-impact-and-challenges-in-pulmonary-disease-management/Medxy AIen2026-09-20T09:17:36-07:00East Asia-Specific Mycobacterium massiliense ST120: Phylogenomics, Clinical Impact, and Challenges in Pulmonary Disease Management https://news.medxy.ai/zh/lynx1-phase3-trial/Medxy AIzh2026-09-20T09:17:01-07:00LYNX-1 Ⅲ期试验：0.75%酚妥拉明滴眼液改善暗光视觉障碍 https://news.medxy.ai/ja/fentolamine-eye-drops/Medxy AIja2026-09-20T09:16:34-07:00暗所視障害に対する0.75%フェントラミン点眼液：第3相LYNX-1試験の結果 https://news.medxy.ai/vi/phentolamine-eye-drops/Medxy AIvi2026-09-20T09:16:06-07:00LYNX-1 giai đoạn 3: dung dịch nhỏ mắt phentolamine cho rối loạn thị giác khi ánh sáng yếu https://news.medxy.ai/lynx-1-phase-3-trial-phentolamine-ophthalmic-solution-for-dim-light-vision-disturbances/Medxy AIen2026-09-20T09:15:40-07:00LYNX-1 Phase 3 Trial: Phentolamine Ophthalmic Solution for Dim Light Vision Disturbances https://news.medxy.ai/zh/linc01521-thyroid-cancer/Medxy AIzh2026-09-20T09:14:52-07:00LINC01521 在乳头状甲状腺癌中的作用：预后价值与分子机制探析 https://news.medxy.ai/ja/linc01521-thyroid-cancer-3/Medxy AIja2026-09-20T09:14:29-07:00乳頭状甲状腺癌におけるLINC01521の役割を解明する：予後予測能と分子機序 https://news.medxy.ai/vi/linc01521-thyroid-cancer-2/Medxy AIvi2026-09-20T09:14:02-07:00LINC01521 trong ung thư biểu mô nhú tuyến giáp: ý nghĩa tiên lượng và cơ chế phân tử https://news.medxy.ai/unraveling-the-role-of-linc01521-in-papillary-thyroid-carcinoma-prognostic-potential-and-molecular-mechanisms/Medxy AIen2026-09-20T09:13:36-07:00Unraveling the Role of LINC01521 in Papillary Thyroid Carcinoma: Prognostic Potential and Molecular Mechanisms https://news.medxy.ai/zh/xenotransplantation-liver-failure/Medxy AIzh2026-09-20T09:12:48-07:00急性肝衰竭中的异种移植：以基因修饰猪肝弥合供肝缺口 https://news.medxy.ai/ja/xenotransplantation-liver-failure-2/Medxy AIja2026-09-20T09:12:25-07:00急性肝不全における異種移植：遺伝子改変ブタ肝臓が切り開く臓器ギャップへの橋渡し https://news.medxy.ai/vi/xenotransplantation-liver/Medxy AIvi2026-09-20T09:11:56-07:00Ghép dị loài gan trong suy gan cấp: thu hẹp khoảng cách thiếu hụt tạng ghép bằng gan lợn biến đổi gen https://news.medxy.ai/xenotransplantation-in-acute-liver-failure-bridging-the-organ-gap-with-genetically-modified-porcine-livers/Medxy AIen2026-09-20T09:11:30-07:00Xenotransplantation in Acute Liver Failure: Bridging the Organ Gap with Genetically Modified Porcine Livers https://news.medxy.ai/zh/gut-vascular-barrier/Medxy AIzh2026-09-20T09:10:49-07:00肠-血管屏障失守：巨噬细胞功能障碍如何推动肝硬化中的细菌移位 https://news.medxy.ai/ja/liver-cirrhosis-barrier-breakdown/Medxy AIja2026-09-20T09:10:25-07:00肝硬変における腸管―血管バリア破綻を読み解く：マクロファージ機能障害が細菌トランスロケーションを駆動する https://news.medxy.ai/vi/vascular-barrier-breakdown/Medxy AIvi2026-09-20T09:09:56-07:00Khi hàng rào ruột-mạch máu bị phá vỡ: Rối loạn đại thực bào thúc đẩy chuyển vị vi khuẩn trong xơ gan https://news.medxy.ai/dissecting-gut-vascular-barrier-failures-macrophage-dysfunction-drives-bacterial-translocation-in-cirrhosis/Medxy AIen2026-09-20T09:09:31-07:00Dissecting Gut-Vascular Barrier Failures: Macrophage Dysfunction Drives Bacterial Translocation in Cirrhosis https://news.medxy.ai/zh/postmenopausal-estradiol-range/Medxy AIzh2026-09-20T09:08:49-07:00绝经后女性雌二醇参考范围实现统一：提升激素评估与风险预测准确性的突破 https://news.medxy.ai/ja/75832-2/Medxy AIja2026-09-20T09:08:26-07:00閉経後女性のエストラジオール基準範囲が統一されました https://news.medxy.ai/vi/estradiol-reference-women/Medxy AIvi2026-09-20T09:08:02-07:00Chuẩn hóa khoảng tham chiếu estradiol ở phụ nữ sau mãn kinh: Bước tiến cho đánh giá hormone chính xác và dự đoán nguy cơ https://news.medxy.ai/harmonizing-estradiol-reference-ranges-in-postmenopausal-women-a-breakthrough-for-accurate-hormone-assessment-and-risk-prediction/Medxy AIen2026-09-20T09:07:36-07:00Harmonizing Estradiol Reference Ranges in Postmenopausal Women: A Breakthrough for Accurate Hormone Assessment and Risk Prediction https://news.medxy.ai/zh/adam10-atrial-fibrillation/Medxy AIzh2026-09-20T09:06:55-07:00乳腺癌来源ADAM10：通过心房纤维化介导心房颤动的新机制 https://news.medxy.ai/ja/adam10-atrial-fibrillation-2/Medxy AIja2026-09-20T09:06:31-07:00乳がん由来ADAM10が心房細動を誘発する新機序：心房線維化を介した腫瘍―心臓連関 https://news.medxy.ai/vi/adam10-breast-cancer/Medxy AIvi2026-09-20T09:06:04-07:00ADAM10 có nguồn gốc từ ung thư vú: tác nhân mới làm trung gian rung nhĩ qua xơ hóa nhĩ https://news.medxy.ai/breast-cancer-derived-adam10-a-novel-mediator-of-atrial-fibrillation-through-atrial-fibrosis/Medxy AIen2026-09-20T09:05:38-07:00Breast Cancer-Derived ADAM10: A Novel Mediator of Atrial Fibrillation Through Atrial Fibrosis https://news.medxy.ai/zh/retina-octa-insights/Medxy AIzh2026-09-20T08:57:34-07:00视网膜OCTA：洞察脑小血管病与卒中后认知下降的新窗口 https://news.medxy.ai/ja/75805-2/Medxy AIja2026-09-20T08:57:09-07:00網膜OCTA：脳小血管病と脳卒中後の認知機能低下を解明する新たな窓 https://news.medxy.ai/vi/75804-2/Medxy AIvi2026-09-20T08:56:44-07:00OCTA võng mạc: Một góc nhìn mới về bệnh lý mạch máu nhỏ não và suy giảm nhận thức sau đột quỵ https://news.medxy.ai/retinal-octa-as-a-window-into-cerebral-small-vessel-disease-and-cognitive-decline-post-stroke/Medxy AIen2026-09-20T08:56:15-07:00Retinal OCTA as a Window into Cerebral Small Vessel Disease and Cognitive Decline Post-Stroke https://news.medxy.ai/zh/relapse-b-cell-leukemia/Medxy AIzh2026-09-20T08:55:33-07:00复发/难治性 B 细胞急性淋巴细胞白血病成人首次挽救治疗的预后因素及异基因造血干细胞移植作用 https://news.medxy.ai/ja/b-cell-leukemia-treatment/Medxy AIja2026-09-20T08:55:09-07:00ブリナツモマブ／イノツズマブ オゾガマイシンを用いた初回救援療法における再発／難治性B細胞急性リンパ性白血病成人患者の予後因子と同種造血幹細胞移植の役割 https://news.medxy.ai/vi/allo-hsct-prognosis-b-all/Medxy AIvi2026-09-20T08:54:42-07:00Yếu tố tiên lượng và vai trò của allo-HSCT trong điều trị cứu vãn bậc một ở người lớn mắc B-ALL tái phát/kháng trị điều trị bằng blinatumomab và inotuzumab ozogamicin https://news.medxy.ai/prognostic-factors-and-role-of-allo-hsct-in-first-salvage-therapy-for-adults-with-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia-treated-with-blinatumomab-and-inotuzumab-ozogamicin/Medxy AIen2026-09-20T08:54:17-07:00Prognostic Factors and Role of Allo-HSCT in First Salvage Therapy for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Blinatumomab and Inotuzumab Ozogamicin https://news.medxy.ai/zh/wean-failure-phenotypes-2/Medxy AIzh2026-09-20T08:51:31-07:00有创机械通气撤机失败的三种不同表型：来自WEAN SAFE队列的研究启示 https://news.medxy.ai/ja/wean-failure-phenotypes/Medxy AIja2026-09-20T08:51:11-07:00侵襲的人工呼吸離脱失敗にみられる3つの異なる表現型──WEAN SAFEコホートからの知見 https://news.medxy.ai/vi/wean-failure-types/Medxy AIvi2026-09-20T08:50:44-07:00Ba kiểu hình cai máy khác nhau ở bệnh nhân thất bại thở máy xâm nhập: phát hiện từ đoàn hệ WEAN SAFE https://news.medxy.ai/distinct-weaning-phenotypes-in-invasive-mechanical-ventilation-failures-insights-from-the-wean-safe-cohort/Medxy AIen2026-09-20T08:50:21-07:00Distinct Weaning Phenotypes in Invasive Mechanical Ventilation Failures: Insights from the WEAN SAFE Cohort https://news.medxy.ai/zh/75783-2/Medxy AIzh2026-09-20T08:49:45-07:00低剂量氯胺酮可减少ICU患者阿片类药物用量——一项针对机械通气患者的双盲随机试验结果 https://news.medxy.ai/ja/low-dose-ketamine-icu-opioids/Medxy AIja2026-09-20T08:49:23-07:00低用量ケタミンで ICU のオピオイド使用量を軽減　― 機械換気患者を対象とした二重盲検ランダム化試験からの知見 https://news.medxy.ai/vi/low-dose-ketamine-opioid-reduction/Medxy AIvi2026-09-20T08:49:00-07:00Ketamine liều thấp giúp giảm nhu cầu opioid ở bệnh nhân ICU thở máy: Những phát hiện từ một thử nghiệm ngẫu nhiên mù đôi https://news.medxy.ai/low-dose-ketamine-reduces-opioid-requirements-in-mechanically-ventilated-icu-patients-insights-from-a-double-blind-randomized-trial/Medxy AIen2026-09-20T08:48:38-07:00Low-Dose Ketamine Reduces Opioid Requirements in Mechanically Ventilated ICU Patients: Insights from a Double-Blind Randomized Trial https://news.medxy.ai/zh/icu-survivors-driving-2/Medxy AIzh2026-09-20T08:47:56-07:00ICU幸存者如何安全恢复驾驶：一项全面驾驶评估研究的启示 https://news.medxy.ai/ja/icu-survivors-driving/Medxy AIja2026-09-20T08:47:35-07:00ICU生存者の運転再開を可能にするために：包括的運転評価研究から得られた知見 https://news.medxy.ai/vi/driving-ability-survivors/Medxy AIvi2026-09-20T08:47:12-07:00Khả năng quay lại lái xe ở người sống sót sau ICU: phát hiện từ nghiên cứu đánh giá lái xe toàn diện https://news.medxy.ai/enabling-driving-resumption-in-icu-survivors-insights-from-a-comprehensive-driving-assessment-study/Medxy AIen2026-09-20T08:46:49-07:00Enabling Driving Resumption in ICU Survivors: Insights from a Comprehensive Driving Assessment Study https://news.medxy.ai/ja/75767-2/Medxy AIja2026-09-20T08:46:08-07:00救急診療における診断の卓越性と診断見落としの機会：実践と研究に関する重要なコンセンサスと提言 https://news.medxy.ai/vi/diagnostic-consensus/Medxy AIvi2026-09-20T08:45:29-07:00Đồng thuận mới về chẩn đoán xuất sắc và cơ hội chẩn đoán bị bỏ sót tại khoa Cấp cứu: Khuyến nghị cốt lõi cho thực hành và nghiên cứu https://news.medxy.ai/zh/emergency-diagnosis-consensus/Medxy AIzh2026-09-20T08:44:52-07:00急诊诊断卓越与遗漏诊断机会：实践与研究的关键共识建议 https://news.medxy.ai/defining-diagnostic-excellence-and-missed-diagnostic-opportunity-in-the-emergency-department-key-consensus-recommendations-for-practice-and-research/Medxy AIen2026-09-20T08:44:14-07:00Defining Diagnostic Excellence and Missed Diagnostic Opportunity in the Emergency Department: Key Consensus Recommendations for Practice and Research https://news.medxy.ai/dexmedetomidine-continuous-infusion-to-maintain-sedation-in-severely-agitated-adolescents-in-the-emergency-department-a-case-series-report/Medxy AIen2026-09-20T08:43:24-07:00Dexmedetomidine Continuous Infusion to Maintain Sedation in Severely Agitated Adolescents in the Emergency Department: A Case Series Report https://news.medxy.ai/zh/clinical-research-training/Medxy AIzh2026-09-20T08:42:44-07:00真实临床试验中的医学生研究培训新模式：以双导师与实践带教提升胜任力 https://news.medxy.ai/ja/clinical-research-education/Medxy AIja2026-09-20T08:42:24-07:00医学生の臨床研究教育を刷新する：真正なメンタリングと実践で育む能力向上 https://news.medxy.ai/vi/clinical-research-training-2/Medxy AIvi2026-09-20T08:41:58-07:00Đổi mới đào tạo nghiên cứu lâm sàng cho sinh viên y khoa bậc đại học: Nâng cao năng lực thông qua cố vấn chân thực và thực hành https://news.medxy.ai/innovative-clinical-research-training-for-medical-undergraduates-enhancing-competency-through-authentic-mentorship-and-practice/Medxy AIen2026-09-20T08:41:34-07:00Innovative Clinical Research Training for Medical Undergraduates: Enhancing Competency through Authentic Mentorship and Practice https://news.medxy.ai/enhancing-interprofessional-teamwork-in-icu-developing-entrustable-professional-activities-for-trainees-and-advanced-practice-providers/Medxy AIen2026-09-20T08:40:44-07:00Enhancing Interprofessional Teamwork in ICU: Developing Entrustable Professional Activities for Trainees and Advanced Practice Providers https://news.medxy.ai/ja/medical-ethics-ai/Medxy AIja2026-09-20T08:40:04-07:00AI時代の医療倫理と専門職性：American College of Physicians 2026年ポジションペーパーの要点 https://news.medxy.ai/vi/ethics-professionalism-ai/Medxy AIvi2026-09-20T08:39:24-07:00Đạo đức và tính chuyên nghiệp trong AI và thực hành y khoa: Hướng dẫn then chốt từ American College of Physicians (Bản tuyên bố lập trường 2026) https://news.medxy.ai/zh/ai-medical-ethics/Medxy AIzh2026-09-20T08:38:41-07:00AI与医疗实践中的伦理与专业精神：美国内科医师学会2026年立场文件要点 https://news.medxy.ai/ethics-and-professionalism-in-ai-and-medical-practice-key-guidance-from-the-american-college-of-physicians-2026-position-paper/Medxy AIen2026-09-20T08:38:04-07:00Ethics and Professionalism in AI and Medical Practice: Key Guidance from the American College of Physicians (2026 Position Paper) https://news.medxy.ai/ja/2025-va-dod-lipid-guidelines/Medxy AIja2026-09-20T08:37:07-07:002025年VA/DoD脂質管理ガイドライン要点：臨床医が押さえるべきポイント https://news.medxy.ai/vi/va-dod-lipid-guide/Medxy AIvi2026-09-20T08:36:22-07:00Tóm lược hướng dẫn quản lý lipid VA/DoD 2025: điều bác sĩ lâm sàng cần biết https://news.medxy.ai/zh/2025-lipid-guidelines/Medxy AIzh2026-09-20T08:35:38-07:002025年VA/DoD血脂管理指南速览：临床医生必须掌握的要点 https://news.medxy.ai/a-synopsis-of-the-2025-va-dod-lipid-management-guideline-what-clinicians-need-to-know/Medxy AIen2026-09-20T08:35:02-07:00A Synopsis of the 2025 VA/DoD Lipid Management Guideline: What Clinicians Need to Know https://news.medxy.ai/zh/75710-2/Medxy AIzh2026-09-20T08:33:54-07:00AL型淀粉样变性患者接受自体干细胞移植的当代疗效：一项为期十年多中心研究的启示 https://news.medxy.ai/ja/75708-2/Medxy AIja2026-09-20T08:33:30-07:00ALアミロイドーシスにおける自家幹細胞移植の現代的成績：10年にわたる多施設共同研究からの知見 https://news.medxy.ai/vi/75705-2/Medxy AIvi2026-09-20T08:33:06-07:00Kết quả hiện đại của phương pháp ghép tế bào gốc tự thân trong bệnh amyloidosis AL: Những hiểu biết từ nghiên cứu đa trung tâm kéo dài 10 năm https://news.medxy.ai/contemporary-outcomes-of-autologous-stem-cell-transplantation-in-al-amyloidosis-insights-from-a-decade-long-multicenter-study/Medxy AIen2026-09-20T08:32:44-07:00Contemporary Outcomes of Autologous Stem Cell Transplantation in AL Amyloidosis: Insights from a Decade-Long Multicenter Study https://news.medxy.ai/zh/hodgkin-lymphoma-age-treatment/Medxy AIzh2026-09-20T08:32:05-07:00经典型霍奇金淋巴瘤中年龄、蒽环类药物应用与死亡结局：来自大规模完整人群队列的启示 https://news.medxy.ai/vi/75696-2/Medxy AIvi2026-09-20T08:31:17-07:00Tuổi tác và Anthracycline ảnh hưởng đến tỷ lệ tử vong ở bệnh nhân u lympho Hodgkin https://news.medxy.ai/age-anthracycline-use-and-mortality-outcomes-in-classic-hodgkin-lymphoma-insights-from-a-large-complete-population-cohort/Medxy AIen2026-09-20T08:30:52-07:00Age, Anthracycline Use, and Mortality Outcomes in Classic Hodgkin Lymphoma: Insights from a Large Complete Population Cohort https://news.medxy.ai/zh/clag-m-vs-cpx-351-aml/Medxy AIzh2026-09-20T08:30:07-07:00CLAG-M 与 CPX-351 在医学上不适合强化治疗的 AML 成人中的比较：一项评估生存与缓解结局的随机Ⅱ期研究 https://news.medxy.ai/ja/75686-2/Medxy AIja2026-09-20T08:29:43-07:00急性骨髄性白血病（AML）の医学的に不適格な成人患者におけるCPX-351対CLAG-M https://news.medxy.ai/vi/cpx351-clagm-aml/Medxy AIvi2026-09-20T08:29:14-07:00CPX-351 và CLAG-M ở người lớn mắc AML không đủ điều kiện điều trị tích cực: Thử nghiệm ngẫu nhiên pha 2 đánh giá sống còn và đáp ứng https://news.medxy.ai/cpx-351-versus-clag-m-in-medically-unfit-adults-with-aml-a-phase-2-randomized-study-evaluating-survival-and-response-outcomes/Medxy AIen2026-09-20T08:28:47-07:00CPX-351 versus CLAG-M in Medically Unfit Adults with AML: A Phase 2 Randomized Study Evaluating Survival and Response Outcomes https://news.medxy.ai/zh/sickle-cell-blood-brain-barrier/Medxy AIzh2026-09-20T08:27:21-07:00从蛋白质组学看镰状细胞病中血脑屏障破坏的全身驱动因素 https://news.medxy.ai/ja/blood-brain-barrier-failure/Medxy AIja2026-09-20T08:26:47-07:00プロテオミクスで読み解く、鎌状赤血球症における血液脳関門破綻の全身性ドライバー https://news.medxy.ai/vi/blood-brain-barrier-sickle-cell/Medxy AIvi2026-09-20T08:26:22-07:00Giải mã các yếu tố toàn thân gây gián đoạn hàng rào máu – não trong bệnh hồng cầu hình liềm: Góc nhìn từ phân tích proteomic https://news.medxy.ai/unveiling-the-systemic-drivers-of-blood-brain-barrier-disruption-in-sickle-cell-disease-insights-from-proteomic-profiling/Medxy AIen2026-09-20T08:25:59-07:00Unveiling the Systemic Drivers of Blood-Brain Barrier Disruption in Sickle Cell Disease: Insights from Proteomic Profiling https://news.medxy.ai/zh/integrin-%ce%b1iib%ce%b23-deficiency/Medxy AIzh2026-09-20T08:25:16-07:00整合素 αIIbβ3 缺乏如何通过巨核细胞丝氨酸代谢紊乱削弱血小板生成 https://news.medxy.ai/ja/integrin-deficiency-platelet-formation/Medxy AIja2026-09-20T08:24:49-07:00インテグリン αIIbβ3 欠損は巨核球のセリン代謝異常を介して血小板形成を障害する https://news.medxy.ai/vi/75665-2/Medxy AIvi2026-09-20T08:24:20-07:00Sự thiếu hụt integrin αIIbβ3 làm suy giảm quá trình sản sinh tiểu cầu https://news.medxy.ai/integrin-deficiency-platelets/Medxy AIen2026-09-20T08:23:50-07:00Integrin αIIbβ3 Deficiency Impairs Platelet Formation Through Serine Metabolic Dysregulation in Megakaryocytes https://news.medxy.ai/zh/75658-2/Medxy AIzh2026-09-20T08:23:14-07:00医院转入率对风险调整后结局的影响：一项全国性回顾性队列研究的启示 https://news.medxy.ai/ja/75657-2/Medxy AIja2026-09-20T08:22:50-07:00リスク調整後転帰に対する院外からの転院受け入れ頻度の影響：全国規模のレトロスペクティブ・コホート研究からの知見 https://news.medxy.ai/vi/75656-2/Medxy AIvi2026-09-20T08:22:21-07:00Tác động của tỷ lệ bệnh nhân chuyển đến đối với các kết quả lâm sàng đã hiệu chỉnh theo nguy cơ https://news.medxy.ai/impact-of-hospital-transfer-in-prevalence-on-risk-adjusted-outcomes-insights-from-a-national-retrospective-cohort-study/Medxy AIen2026-09-20T08:21:53-07:00Impact of Hospital Transfer-In Prevalence on Risk-Adjusted Outcomes: Insights from a National Retrospective Cohort Study https://news.medxy.ai/zh/brain-natriuretic-peptide/Medxy AIzh2026-09-20T08:21:01-07:00肺动脉内膜剥脱术后脑钠肽水平：慢性血栓栓塞性肺动脉高压患者的预后生物标志物 https://news.medxy.ai/ja/cns-peptide-biomarker/Medxy AIja2026-09-20T08:20:40-07:00慢性血栓塞栓性肺高血圧症における肺動脈内膜剥離術後の予後バイオマーカーとしての脳性ナトリウム利尿ペプチド https://news.medxy.ai/vi/bnp-pulmonary-endarterectomy/Medxy AIvi2026-09-20T08:20:16-07:00BNP sau phẫu thuật pulmonary endarterectomy: Dấu ấn tiên lượng tử vong ở CTEPH https://news.medxy.ai/brain-natriuretic-peptide-levels-as-a-prognostic-biomarker-after-pulmonary-endarterectomy-in-chronic-thromboembolic-pulmonary-hypertension/Medxy AIen2026-09-20T08:19:53-07:00Brain Natriuretic Peptide Levels as a Prognostic Biomarker After Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension https://news.medxy.ai/zh/fibrosis-exercise-comparison/Medxy AIzh2026-09-20T08:19:12-07:00纤维化性间质性肺疾病中高强度间歇训练与中等强度持续训练的比较：随机对照试验的启示 https://news.medxy.ai/ja/75647-2/Medxy AIja2026-09-20T08:18:53-07:00線維化性間質性肺疾患における高強度インターバルトレーニングと中等強度持続トレーニングの比較：ランダム化比較試験からの示唆 https://news.medxy.ai/vi/hiit-vs-mit-fibrosis/Medxy AIvi2026-09-20T08:18:24-07:00Huấn luyện ngắt quãng cường độ cao so với huấn luyện liên tục cường độ vừa trong bệnh phổi kẽ xơ hóa: Góc nhìn từ một thử nghiệm ngẫu nhiên có đối chứng https://news.medxy.ai/evaluating-high-intensity-interval-training-versus-moderate-intensity-continuous-training-in-fibrotic-interstitial-lung-disease-insights-from-a-randomized-controlled-trial/Medxy AIen2026-09-20T08:17:59-07:00Evaluating High Intensity Interval Training Versus Moderate Intensity Continuous Training in Fibrotic Interstitial Lung Disease: Insights from a Randomized Controlled Trial https://news.medxy.ai/zh/glp-1-sleep-apnea/Medxy AIzh2026-09-20T08:17:18-07:00GLP-1受体激动剂能否预防2型糖尿病中的阻塞性睡眠呼吸暂停？英国大型队列研究提示无明显获益 https://news.medxy.ai/ja/75642-2/Medxy AIja2026-09-20T08:16:54-07:00GLP-1受容体作動薬は2型糖尿病患者における閉塞性睡眠時無呼吸を予防できるか？ https://news.medxy.ai/vi/glp-1-receptor-agonists-sleep-apnea-prevention/Medxy AIvi2026-09-20T08:16:27-07:00Chất chủ vận thụ thể GLP-1 và phòng ngừa hội chứng ngưng thở khi ngủ do tắc nghẽn ở đái tháo đường típ 2: Bằng chứng từ một nghiên cứu đoàn hệ lớn tại Vương quốc Anh https://news.medxy.ai/glp-1-receptor-agonists-and-the-prevention-of-obstructive-sleep-apnea-in-type-2-diabetes-insights-from-a-large-uk-cohort-study/Medxy AIen2026-09-20T08:16:02-07:00GLP-1 Receptor Agonists and the Prevention of Obstructive Sleep Apnea in Type 2 Diabetes: Insights from a Large UK Cohort Study